Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf

Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf is offered by Yinhua, a leading player in the field of passive investments.

The total expense ratio of Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf is 0.6%, which means that investors pay 60 CNY per 10,000 CNY in investment capital annually.

The ETF is listed in CNY.

European investors may incur additional costs for currency exchange and transaction fees.

No, Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf does not comply with the EU UCITS investor protection directives.

Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf tracks the performance of the China Securities Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Gross.

Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf is domiciled in CN.

The fund was launched on 1/3/2024.

The Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf mainly invests in Healthcare companies.

The NAV of Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf amounts to 690,545.86 CNY.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.